Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: Results of a phase i dose-escalating study in patients with advanced solid malignancies
Hepato- and neuro-toxicity are schedule independent dose-limiting adverse events for this marine compound, as illustrated by this and other early clinical trials.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency